Cancers, Vol. 16, Pages 1421: The Micro-Immunotherapy Medicine 2LPAPI & reg; Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells
Cancers, Vol. 16, Pages 1421: The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells
Cancers doi: 10.3390/cancers16071421
Authors:
Camille Jacques
Flora Marchand
Mathias Chatelais
Virginie Albinet
Claire Coustal
Ilaria Floris
Human papillomavirus (HPV) is the second most common infectious agent causing cancer. Persistent infection with high-risk (HR)-HPV can lead to cervical intra-epithelial neoplasia and cervical carcinomas (CC). While host immune response is necessary for viral clearance, chronic immune activation contributes to a low-grade inflammation that can ultimately lead to carcinogenesis. The micro-immunotherapy medicine (MIM) 2LPAPI® could be a valuable tool to manage the clearance of the virus and reduce the risk of developing CC. In this in vitro study, we aimed to investigate its mode of action. We showed that actives from the MIM increased the IL-6, IFN-γ, and IP-10 secretion in human peripheral blood mononuclear cells (PBMCs) exposed to peptides derived from the HPV-16 capsid (HPV16(L1)). This could reflect an increase in the immune activity toward HPV-16. At the same time, some active substances reduced the lympho-proliferation and the expression of T-cell activation markers. Finally, some of the MIM actives displa...
Source: Cancers - Category: Cancer & Oncology Authors: Camille Jacques Flora Marchand Mathias Chatelais Virginie Albinet Claire Coustal Ilaria Floris Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Epithelial Cancer | Genital Warts | Human Papillomavirus (HPV) | Immunotherapy | Study